Pharmacokinetics of HLD200, a Delayed-Release and Extended-Release Methylphenidate: Evaluation of Dose Proportionality, Food Effect, Multiple-Dose Modeling, and Comparative Bioavailability with Immediate-Release Methylphenidate in Healthy Adults

Journal of Child and Adolescent Psychopharmacology
Tao LiuBev Incledon

Abstract

HLD200, an oral, once-daily, evening-dosed, delayed-release, and extended-release methylphenidate (DR/ER-MPH), was designed to provide efficacy from the early morning, throughout the day, and into the evening to individuals with attention-deficit/hyperactivity disorder. The objectives were to evaluate DR/ER-MPH pharmacokinetic (PK) properties in healthy adults, including dose proportionality, food effect, the potential of accumulation using multiple-dose modeling, and bioavailability compared to an immediate-release MPH (IR MPH). Three open-label, single-dose, crossover studies were conducted, all with a 7-day washout between treatments. In Study I, 20 subjects received evening-dosed DR/ER-MPH (20 and 100 mg) followed by a medium-fat breakfast; 13 subjects received a subsequent 100-mg dose of DR/ER-MPH followed by a low-fat breakfast. In Study II, 18 subjects were evaluated after receiving evening-dosed DR/ER-MPH (100 mg) under 3 conditions: immediately after a high-fat meal, sprinkled on applesauce, and in a fasted state. In Study III, 11 and 12 subjects received evening-dosed DR/ER-MPH (100 mg) and morning-dosed IR MPH (20 mg), respectively. DR/ER-MPH demonstrated dose proportionality between 20- and 100-mg doses. DR/ER-MPH P...Continue Reading

References

Feb 1, 1994·Biological & Pharmaceutical Bulletin·T KimuraT Nakayama
Feb 8, 2006·Journal of Abnormal Child Psychology·Carol K WhalenJoseph A Johnston
Jun 22, 2007·Journal of the American Academy of Child and Adolescent Psychiatry·Steven Pliszka, UNKNOWN AACAP Work Group on Quality Issues
Oct 12, 2010·AAPS PharmSciTech·Laxma R NagavelliLucinda Buhse
Oct 18, 2011·Pediatrics·UNKNOWN Subcommittee on Attention-Deficit/Hyperactivity DisorderSusanna Visser
Apr 25, 2013·Expert Opinion on Drug Metabolism & Toxicology·Rafael Maldonado
Apr 27, 2016·Expert Opinion on Pharmacotherapy·Ann C Childress
Nov 28, 2017·Journal of Child and Adolescent Psychopharmacology·Steven R PliszkaJeffrey H Newcorn

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy
contraception

Clinical Trials Mentioned

NCT02493777

Software Mentioned

Phoenix WinNonlin
SAS
Prism

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.